First-generation (Erlotinib and Gefitinib) and second-generation (Dacomitinib and Afatinib) EGFR-TKIs are used to treat cancers harboring L858R and Ex19Del; T790M is observed usually in cancers that have acquired drug resistance due to selective pressure during clinical care [14, 15]. Here, EGFR is linked to cancer.